Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tango Therapeutics Inc. (TNGX:NASDAQ), powered by AI.
Tango Therapeutics Inc. is currently trading at $30.93. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Tango Therapeutics Inc. on Alpha Lenz.
View Tango Therapeutics Inc.'s valuation metrics on Alpha Lenz.
“Tango Therapeutics Inc.'s ROE is -37.2%. Explore profitability and growth together.”
Ask for details →Tango Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of precision cancer medicines. Its primary objective is to identify novel therapeutic targets and develop treatments based on synthetic lethality, an approach that exploits vulnerabilities within cancer cells for effective treatment. Tango Therapeutics operates in the biotechnology and healthcare sectors, impacting areas such as cancer research, drug development, and personalized medicine. The company harnesses advanced technologies in genomics and bioinformatics to uncover potential drug candidates that are specifically tailored to the genetic profile of different cancer types. Tango Therapeutics plays a crucial role in the treatment landscape by providing innovative solutions that are designed to improve outcomes for cancer patients. Established as a leader in precision oncology, the company contributes to the growing field of targeted therapies, aiming to transform how cancer is treated across the globe.
“Tango Therapeutics Inc.'s ROE is -37.2%. Explore profitability and growth together.”
Ask for details →Tango Therapeutics Inc. (ticker: TNGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 155 employees.
The current price is $30.93 with a P/E ratio of -x and P/B of -x.
ROE is -37.23% and operating margin is -178.39%. Annual revenue is $62M.